French company having developed blood biomarkers for psychiatry looking for a coordinator in order to submit a joint proposal for Horizon 2020 SC1-BHC-06-2020 call for project. The project aims at developing a platform to help physicians to diagnose psychiatric disorders (especially depression and bipolar disorders). This platform will include current diagnostics gold standards and innovative markers. The coordinator could be a university hospital or end-user company experienced in EU projects.
The idea is to change the game in psychiatry where the diagnosis today is inaccurate and subjective because it often relies solely on symptoms evaluation, based on the expression of patients and clinicians' observations. This may lead to years of misdiagnosis and inadequate treatment, which has dramatic consequences on patients' health, life and social inclusion. The project targets more specifically depression and bipolar disorder. These two diseases are complex for clinicians as they could be confused. As a result, patients could suffer for a long diagnostic wavering and inadequate treatment. So the project will focus on tools allowing clinicians to confirm the diagnosis of unipolar or bipolar depression very early and to accelerate therapeutic decisions. The company developed blood biomarkers (based on epigenetics and artificial intelligence) for psychiatric diseases such as depression and bipolar disorder and is applying to Horizon 2020 call for project SC1-BHC-06-2020: Digital diagnostics – developing tools for supporting clinical decisions by integrating various diagnostic data. The Commission considers that proposals requesting a contribution from the EU of between EUR 8 and 15 million would allow this specific challenge to be addressed appropriately. Through this project the objective is to develop a whole platform to help physicians to diagnose those psychiatric disorders, including current gold standards (clinical exams, clinical scales) but also innovative markers (blood biomarkers, electrophysiological markers, etc.). According to the expectations of the call, the goal is to validate these new methods, to integrate them into a digital platform, enabling the physicians to diagnose (initial diagnosis, repeat diagnosis in case of change of symptoms, etc.) as well as monitor the patient (evolution of the disease, response to treatment, etc.). This platform could then be deployed in hospitals across Europe. The consortium will be mainly composed of: 1) companies developing complementary innovative biomarkers (including the company and another French SME developing electrophysiological markers), 2) clinical centres, as research partners as well as end-users (depending on the coordinator, several clinical centres could be included in the consortium). Others partners may be: clinical labs, digital companies for the design of the platform, other researchers, etc. The project still needs a leader, which will manage the project, coordinate all partners, and leads some of the workpackages. Deadline for the EoI : 2020/04/07 Official deadline for the call : 2020/04/07 Anticipated duration of the project : 3 years
06001005 Diagnostics, Diagnosis
06001014 Neurology, Brain Research
06002002 Cellular and Molecular Biology
06005004 Remote diagnostics
Market application codes
05001001 Diagnostic services
05001003 Differential diagnosis
05001005 Molecular diagnosis
05005022 Other clinical medicine
Type of partner sought
The company is looking for a coordinator to submit a proposal for call SC1-BHC-06-2020: Digital diagnostics – developing tools for supporting clinical decisions by integrating various diagnostic data. The partner could be either a university hospital active in psychiatry, or a end-user company (pharma company or diagnostics company). The future coordinator should be experienced in managing EU projects and able to pilot different workpackages (clinical studies, designing a digital platform, dissemination...). The future coordinator will be leading the writing of the proposal (deadline : April 7th 2020), with the support of the other members of the consortium (SME, and clinical partners).